



**indoco remedies limited**

INDOCO HOUSE, 166 C. S. T. ROAD, SANTACURZ (EAST) , MUMBAI -400 098 (INDIA) ● Website : www.indoco.com  
PHONES : (91-22) 6287 1000 / 3386 1250 ● CIN : L85190MH1947PLC005913 ● GSTIN: 27AACIO380C1Z3

May 26, 2020

To The Manager Listing Department <b>National Stock Exchange of India Limited</b> 'Exchange Plaza', C - 1, Block G, Bandra-Kurla Complex, <u>Bandra (E), Mumbai 400051.</u> Scrip Code: INDOCO	To <b>BSE Limited</b> Corporate Relationship Department 1 <sup>st</sup> Floor, New Trading Ring, Phiroze Jeejeebhoy Towers Dalal Street <u>Mumbai 400001</u> Scrip Code : 532612
---	--

Dear Sirs,

**Sub: Disclosure under Regulation 30 of LODR Regulations 2015**  
**Indoco receives USFDA approval for Succinylcholine Chloride Injection USP**

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find Press Release for your information and record.

For Indoco Remedies Limited

26-05-2020

X 

Jayshankar Menon

Signed by: Jayshankar Menon  
Jayshankar Menon  
Company Secretary  
A11067

# PRESS RELEASE

## **Indoco receives USFDA approval for Succinylcholine Chloride Injection USP**

**May 26, 2020, Mumbai:** Indoco Remedies announces receipt of Approval of its ANDA for Succinylcholine Chloride Injection USP 200 mg / 10 ml (20 mg / ml) Multi-dose vial, therapeutically equivalent to the Reference Listed Drug (RLD) Quelicin Injection of Hospira, Inc.

Succinylcholine Chloride Injection is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

The US market size of Succinylcholine Chloride Injection is of 72 million USD (6 million vials), as per IMS data for the year ending March, 2020.

The product is being used for some patients infected with Corona virus (COVID-19).

Commenting on this positive outcome, **Ms. Aditi Kare Panandikar, Managing Director – Indoco Remedies Ltd. said**, “The receipt of this USFDA approval, in a record time of just 4 months from the date of filing ANDA, is very encouraging. It brings an enormous opportunity to Indoco to serve the patients in these trying times.”

### **About Indoco Remedies Limited:**

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD 140 million Company, employs over 6000 people including more than 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by USFDA, UK-MHRA, TGA-Australia, PMDA-Japan, etc. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from around 3,10,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain Management, Gastro-intestinal, Ophthalmic, Cardiovascular, Anti-Diabetics, Anti-Obesity, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Oxipod, Cital, ATM, Cloben-G, Sensoform, Sensodent-KF, Karvol Plus, Glychek, Kidodent, Carmicide, Bactogard, etc. On the international front, Indoco has tie-ups with large generic companies like Watson (Actavis) – USA and ASPEN-South Africa.

For more details on Indoco, you may visit [www.indoco.com](http://www.indoco.com)

### **For Media Inquiries Please Contact:**

**Vilas V. Nagare**

Mobile: 9820215745

E-mail: [vilasn@indoco.com](mailto:vilasn@indoco.com) / [corpcom@indoco.com](mailto:corpcom@indoco.com)